Lesson plan
Cibinetide
Cibinetide ( ; ; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions. It was under development for the treatment of depressive disorders, but development for this indication was discontinued. The drug is under development by Araim Pharmaceuticals. Modified derivatives with a longer duration of action have also been developed.
Article summary
Cibinetide ( ; ; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions. It was under development for the treatment of depressive disorders, but development for this indication was discontinued. The drug is under development by Araim Pharmaceuticals. Modified derivatives with a longer duration of action have also been developed.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.